Skip to content

Propolis supplementation AND Coronavirus

The effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200802048267N1
Enrollment
80
Registered
2020-10-20
Start date
2020-08-22
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid 19. Covid-19

Interventions

Intervention 1: Intervention group: Participants in the intervention group will receive an identical propolis tablet (containing 300?mg Iranian green propolis) three times a day, before breakfast, lun

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: A willing to participate with written informed consent The diagnosis of coronavirus based on the PCR test.

Exclusion criteria

Exclusion criteria: Current use of warfarin Current use of Propolis Supplement Presence of sensitivity to bee products

Design outcomes

Primary

MeasureTime frame
Erythrocyte Sedimentation Rate. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Severity and number of coughs. Timepoint: Day 1 and day 14. Method of measurement: Cough visual analogue scale (VAS).;Respiratory Rate. Timepoint: day 1 and day 14. Method of measurement: The number of breaths a person takes per minute.;Chest CT scan. Timepoint: Day 1 and day 14. Method of measurement: X ray imaging.;High-sensitivity C-reactive protein. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.

Secondary

MeasureTime frame
Body temperature. Timepoint: Day 1 and day 14. Method of measurement: Clinical Thermometer.;Alanine aminotransferase Activity. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Aspartate aminotransferase Activity. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Superoxide dismutase Activity. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.;Albumin. Timepoint: Day 1 and day 14. Method of measurement: Colorimetric method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKarim Sohrabi

Esfahan University of Medical Sciences

sohrabi@mail.mui.ac.ir+98 31 3822 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 25, 2026